Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Xelevia - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Xelevia

Approved

STANDARD

Xelevia

Merck Sharp & Dohme Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 836d3836e0b1dbbe
Company: Merck Sharp & Dohme Ltd.
Type: Standard

Approval Details

Approval Id: 836d3836e0b1dbbe
Drug Approval Philippines Name: Xelevia
Product Name: Xelevia
Registration Number: DRP-5944-01
Brand Name: Xelevia
Generic Name: Sitagliptin
Dosage Form: Film-Coated Tablet
Dosage Strength: 100 mg
Manufacturer: Merck Sharp & Dohme Ltd.
Importer: Merck Sharp & Dohme (I.A.) LLC
Distributor: Essex Pharmaceuticals Inc.
Issuance Date: 29 November 2024
Expiry Date: 28 January 2030
Pharmacologic Category: Dipeptidyl Peptidase-4 Inhibitor
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

836d3836e0b1dbbe

Type

Standard

Back to Philippines FDA Approvals